Sarepta Therapeutics (SRPT) Could Be 28% Below Fair Value As New CEO Takes OverSimplywall·6 hours agoSRPT+0.16%SRPU0.00%
Tracking Specialized Equities: Fox's Roku Buyout and Key C-Suite Reshuffles Drive Idiosyncratic FlowGlobal Report·13 hours agoZTS-2.44%SRPT+0.16%
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from BrokeragesMarket Beat·16 hours agoSRPT+0.16%SRPU0.00%
Sarepta grants new CEO Severino options for 2,224,342 shares at $17.74, plus 756,104 RSUsPUBT·1 day ago, 04:21 PMSRPT+0.16%SRPU0.00%
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer | SRPT Stock NewsStockTitan·Jul 26 at 11:30 PMSRPT+0.16%SRPU0.00%
Sarepta Therapeutics to report Q2 results after market close, host conference callPUBT·Jul 22 at 07:31 AMSRPT+0.16%SRPU0.00%
The Barbell Market of 2026: Balancing Gene Therapies With High-Leverage ETFsGlobal Report·Jul 18 at 04:13 AMDV-4.17%BNR+0.34%
